Correlation of recist, computed tomography morphological response, and pathological regression in hepatic metastasis secondary to colorectal cancer : The avamet study
Vera, Ruth (Instituto de investigaciones Sanitarias de Navarra (IdISNA))
Gómez, María Luisa (Complejo Hospitalario de Navarra)
Ayuso Colella, Juan Ramón (Hospital Clínic i Provincial de Barcelona)
Figueras, Joan (Hospital Universitari de Girona Doctor Josep Trueta)
García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón)
Martínez, Virginia (Hospital Universitario La Paz (Madrid))
Lacasta, Adelaida (Hospital de Donostia (Sant Sebastià, País Basc))
Ruiz-casado, Ana (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Safont, María José (Hospital General Universitario de Valencia)
Aparicio Urtasun, Jorge (Hospital Universitari i Politècnic La Fe (València))
Campos, Juan Manuel (Hospital Arnau de Vilanova (València))
Cámara, Juan Carlos (Hospital Universitario Fundación Alcorcón)
Martín-Richard, Marta (Institut d'Investigació Biomèdica Sant Pau)
Montagut Viladot, Clara (Hospital del Mar (Barcelona, Catalunya))
Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Vieitez, Jose María (Hospital Universitario Central de Asturias)
Falcó, Esther (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears))
Jorge, Mónica (Hospital Xeral Cíes)
Marín, Miguel (Hospital Clínico Universitario Virgen de la Arrixaca (El Palmar, Múrcia))
Salgado, Mercedes (Complejo Hospitalario de Ourense)
Viúdez, Antonio (Instituto de investigaciones Sanitarias de Navarra (IdISNA))
Universitat Autònoma de Barcelona

Date:	2020
Abstract:	The prospective phase IV AVAMET study was undertaken to correlate response evaluation criteria in solid tumors (RECIST)-defined response rates with computed tomography-based morphological criteria (CTMC) and pathological response after liver resection of colorectal cancer metastases. Eligible patients were aged ≥18 years, with Eastern Cooperative Oncology Group (ECOG) performance status 0/1 and histologically-confirmed colon or rectal adenocarcinoma with measurable liver metastases. Preoperative treatment was bevacizumab (7. 5 mg on day 1) + XELOX (oxaliplatin 130 mg/m, capecitabine 1000 mg/m bid on days 1-14 q3w). After three cycles, response was evaluated by a multidisciplinary team. Patients who were progression-free and metastasectomy candidates received one cycle of XELOX before undergoing surgery 3-5 weeks later, followed by four cycles of bevacizumab + XELOX. A total of 83 patients entered the study; 68 were eligible for RECIST, 67 for CTMC, and 51 for pathological response evaluation. Of these patients, 49% had a complete or partial RECIST response, 91% had an optimal or incomplete CTMC response, and 81% had a complete or major pathological response. CTMC response predicted 37 of 41 pathological responses versus 23 of 41 responses predicted using RECIST (p = 0. 008). Kappa coefficients indicated a lack of correlation between the results of RECIST and morphological responses and between morphological and pathological response rates. CTMC may represent a better marker of pathological response to bevacizumab + XELOX than RECIST in patients with potentially-resectable CRC liver metastases.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Antiangiogenics ; Bevacizumab ; Computed tomography-based morphological criteria ; Metastatic colorectal cancer ; Neoadjuvant chemotherapy
Published in:	Cancers, Vol. 12 Núm. 8 (august 2020) , p. 1-12, ISSN 2072-6694

DOI: 10.3390/cancers12082259
PMID: 32806731

11 p, 1.2 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles